Literature DB >> 35178178

Inhibitor-Dependent Usage of the S1' Specificity Pocket of ER Aminopeptidase 2.

Anastasia Mpakali1, Dimitris Georgiadis2, Efstratios Stratikos1,3, Petros Giastas4,5.   

Abstract

Endoplasmic reticulum aminopeptidase 2 (ERAP2) is an intracellular enzyme involved in the processing of antigenic peptides intended for presentation by major histocompatibility complex class I (MHCI) molecules. Because of its role in regulating immune responses, ERAP2 is an emerging pharmacological target. Phosphinic pseudopeptides are potent transition-state analogue inhibitors of ERAP2. Previous structure-activity studies have revealed a complex but ambiguous relationship between the occupation of putative specificity pockets and the inhibitor efficacy. To address these problems, we solved crystal structures of ERAP2 in complex with two phosphinic pseudotripeptide inhibitors. Both compounds are found in the catalytic site in a canonical orientation for transition-state analogues and utilize the S1 and S2' pockets in a similar fashion. Strikingly, their P1' side chains exhibit different orientations and make interactions with distinct shallow pockets near the ERAP2 active site. These structures suggest that S1' pocket usage in ERAP2 may be inhibitor-dependent and constitute useful starting templates for the further optimization of this class of compounds.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35178178      PMCID: PMC8842112          DOI: 10.1021/acsmedchemlett.1c00582

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

Review 1.  The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides.

Authors:  Alfred L Goldberg; Paolo Cascio; Tomo Saric; Kenneth L Rock
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

Review 2.  Processing of antigenic peptides by aminopeptidases.

Authors:  Akira Hattori; Masafumi Tsujimoto
Journal:  Biol Pharm Bull       Date:  2004-06       Impact factor: 2.233

3.  Discovery of potent and selective inhibitors of human aminopeptidases ERAP1 and ERAP2 by screening libraries of phosphorus-containing amino acid and dipeptide analogues.

Authors:  Ewelina Węglarz-Tomczak; Stamatia Vassiliou; Artur Mucha
Journal:  Bioorg Med Chem Lett       Date:  2016-06-25       Impact factor: 2.823

Review 4.  Influence of ERAP1 and ERAP2 gene polymorphisms on disease susceptibility in different populations.

Authors:  Yufeng Yao; Nannan Liu; Ziyun Zhou; Li Shi
Journal:  Hum Immunol       Date:  2019-02-21       Impact factor: 2.850

Review 5.  The genetics, structure and function of the M1 aminopeptidase oxytocinase subfamily and their therapeutic potential in immune-mediated disease.

Authors:  Aimee L Hanson; Craig J Morton; Michael W Parker; Darrell Bessette; Tony J Kenna
Journal:  Hum Immunol       Date:  2018-11-09       Impact factor: 2.850

6.  ERAP1-ERAP2 dimerization increases peptide-trimming efficiency.

Authors:  Irini Evnouchidou; Mirjana Weimershaus; Loredana Saveanu; Peter van Endert
Journal:  J Immunol       Date:  2014-06-13       Impact factor: 5.422

7.  Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses.

Authors:  Efthalia Zervoudi; Emmanuel Saridakis; James R Birtley; Sergey S Seregin; Emma Reeves; Paraskevi Kokkala; Yasser A Aldhamen; Andrea Amalfitano; Irene M Mavridis; Edward James; Dimitris Georgiadis; Efstratios Stratikos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

8.  High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor.

Authors:  Petros Giastas; Margarete Neu; Paul Rowland; Efstratios Stratikos
Journal:  ACS Med Chem Lett       Date:  2019-02-13       Impact factor: 4.345

Review 9.  The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Anastasia Mpakali; Efstratios Stratikos
Journal:  Cancers (Basel)       Date:  2021-01-04       Impact factor: 6.639

10.  ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing.

Authors:  Hanna Chen; Lenong Li; Mirjana Weimershaus; Irini Evnouchidou; Peter van Endert; Marlene Bouvier
Journal:  Sci Rep       Date:  2016-08-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.